Your session is about to expire
← Back to Search
Interleukin-6 Inhibitor
Personalized Arthritis Medication for Rheumatoid Arthritis (SUPRA Trial)
N/A
Recruiting
Research Sponsored by Marie Hudson, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA
Age ≥ 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
SUPRA Trial Summary
This trialaims to develop personalized treatments for rheumatoid arthritis, so that the right drug is given to the right patient at the right time. #PersonalizedMedicine
Who is the study for?
The SUPRA trial is for adults over 18 with Rheumatoid Arthritis who haven't improved after standard treatments. It's split into two parts: one for those needing a second-line treatment, and another for those where TNF inhibitors didn't work. Participants must be able to consent and fill out forms in English or French.Check my eligibility
What is being tested?
This study tests different drugs (TNFi, JAKi, Anti-IL6) to find the best personalized treatment for Rheumatoid Arthritis patients. The goal is to match the right drug to each patient based on their specific needs at the correct time.See study design
What are the potential side effects?
Potential side effects of these arthritis medications may include increased risk of infections, possible liver issues, changes in blood counts, and reactions at injection sites. Each medication has its own set of possible side effects that can vary from person to person.
SUPRA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with rheumatoid arthritis according to the 2010 criteria.
Select...
I am 18 years old or older.
SUPRA Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Patient-reported outcomes (function, health-related quality of life, fatigue)
Prompt access to drugs
Proportion of eligible patients who accept to participate
+5 moreSUPRA Trial Design
4Treatment groups
Active Control
Group I: Sub-study 2 JAKiActive Control1 Intervention
JAKi - tofacitinib (JAK1/3 inhibitor), baricitinib (JAK 1/2 inhibitor) or upadacitinib (JAK1 inhibitor)
Group II: Sub-study 1 TNFiActive Control1 Intervention
TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein), adalimumab (monoclonal antibody), golimumab (monoclonal antibody), or certolizumab (pegylated fragment of a monoclonal antibody)
Group III: Sub-study 1 Anti-IL6Active Control1 Intervention
Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
Group IV: Sub-study 2 Anti-IL6Active Control1 Intervention
Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
Find a Location
Who is running the clinical trial?
Lady Davis InstituteOTHER
43 Previous Clinical Trials
4,957 Total Patients Enrolled
Montreal General HospitalOTHER
17 Previous Clinical Trials
9,962 Total Patients Enrolled
McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER
442 Previous Clinical Trials
159,099 Total Patients Enrolled
4 Trials studying Rheumatoid Arthritis
1,552 Patients Enrolled for Rheumatoid Arthritis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not responded to standard arthritis treatments and qualify for advanced therapy.I have another inflammatory condition like lupus that needs specific treatment.I have been diagnosed with rheumatoid arthritis according to the 2010 criteria.I cannot take certain arthritis medications due to an active infection, current cancer, severe organ issues, history of blood clots (unless I'm on blood thinners), high risk of heart disease, or because I am pregnant/breastfeeding.I am 18 years old or older.I have taken biologic or targeted synthetic DMARDs for my condition.
Research Study Groups:
This trial has the following groups:- Group 1: Sub-study 2 JAKi
- Group 2: Sub-study 1 TNFi
- Group 3: Sub-study 1 Anti-IL6
- Group 4: Sub-study 2 Anti-IL6
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there an ongoing recruitment process for this clinical investigation?
"According to clinicaltrials.gov, this experiment is still recruiting participants. It was made available on the 1st of February in 2021 and underwent its most recent update a day later."
Answered by AI
How many people are being enrolled in this clinical research study?
"Affirmative. The information hosted on clinicaltrials.gov suggests that this experiment is presently seeking participants, with its original posting having been February 1st 2023 and the latest update occurring on February 2nd of the same year. This trial demands 75 patients to be recruited from a solitary location."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger